Vistagen Therapeutics Files 10-Q for Q3 2024

TL;DR

**VISTAGEN THERAPEUTICS FILES 10-Q FOR DEC 31, 2024**

AI Summary

Vistagen Therapeutics, Inc. filed a 10-Q for the period ending December 31, 2024. The company, incorporated in Nevada, is in the pharmaceutical preparations industry. Their fiscal year ends on March 31st, and their business address is in South San Francisco, California.

Why It Matters

This filing provides an update on Vistagen Therapeutics' financial performance and operational status for the third quarter of their fiscal year 2024, which is crucial for investors to assess the company's progress.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Vistagen Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-12-31 — Period End Date (The 10-Q covers financial information up to this date.)
• 2025-02-13 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

• Vistagen Therapeutics, Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of reporting period
• 2025-02-13 (date) — Filing date
• South San Francisco, CA (location) — Business address

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market

Filing Documents

• vtgn-20241231.htm (10-Q) — 1240KB
• vtgn-20241231xexx311.htm (EX-31.1) — 10KB
• vtgn-20241231xexx312.htm (EX-31.2) — 10KB
• vtgn-20241231xexx32.htm (EX-32) — 5KB
• 0001411685-25-000019.txt ( ) — 4952KB
• vtgn-20241231.xsd (EX-101.SCH) — 34KB
• vtgn-20241231_cal.xml (EX-101.CAL) — 39KB
• vtgn-20241231_def.xml (EX-101.DEF) — 143KB
• vtgn-20241231_lab.xml (EX-101.LAB) — 488KB
• vtgn-20241231_pre.xml (EX-101.PRE) — 319KB
• vtgn-20241231_htm.xml (XML) — 434KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statement s of Changes in Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 5 Notes to the Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 25

Controls and Procedures

Item 4. Controls and Procedures 25

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 79

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 79

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 79

Other Information

Item 5. Other Information 79

Exhibits

Item 6. Exhibits 80

SIGNATURES

SIGNATURES 81 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements VISTAGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) December 31, 2024 March 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 74,715 $ 119,166 Marketable securities 13,845 - Prepaid expenses and other current assets 1,381 1,506 Total current assets 89,941 120,672 Property and equipment, net 428 435 Right-of-use asset - operating lease 1,461 1,820 Other assets 477 726 Total assets $ 92,307 $ 123,653 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities: Accounts payable $ 1,039 $ 1,547 Accrued expenses 5,469 2,235 Deferred revenue - current portion 2,510 791 Operating lease obligation - current portion 603 550 Total current liabilities 9,621 5,123 Deferred revenue - non-current portion 454 2,674 Operating lease obligation - non-current portion 1,110 1,570 Total liabilities 11,185 9,367 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized at December 31, 2024 and March 31, 2024; no shares outstanding at December 31, 2024 and March 31, 2024 - - Common stock, $ 0.001 par value; 325,000,000 shares authorized at December 31, 2024 and March 31, 2024; 28,321,216 and 27,029,731 shares issued at December 31, 2024 and March 31, 2024, respectively 28 27 Additional paid-in capital 479,048 474,441 Treasury stock, at cost, 4,522 shares of common stock held at December 31, 2024 and March 31, 2024 ( 3,968 ) ( 3,968 ) Accumulated other comprehensive income 11 - Accumulated deficit ( 393,997 ) ( 356,214 ) Total stockholders' equity 81,122 114,286 Total liabilities and stockholders' equity $ 92,307 $ 123,653 See accompanying notes to unaudited condensed consolidated financial statements. 1 Table of Contents VISTAGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (in th

View Full Filing

View this 10-Q filing on SEC EDGAR